UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 179 filers reported holding UNIQURE NV in Q4 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $86,385 | -36.5% | 12,874 | +8.4% | 0.00% | 0.0% |
| Q2 2023 | $136,110 | -44.6% | 11,877 | -2.7% | 0.00% | -50.0% |
| Q1 2023 | $245,869 | -8.6% | 12,208 | +2.9% | 0.00% | -33.3% |
| Q4 2022 | $269,025 | +25.7% | 11,867 | +4.0% | 0.00% | +50.0% |
| Q3 2022 | $214,000 | +1.9% | 11,409 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $210,000 | -30.2% | 11,272 | +19.9% | 0.00% | 0.0% |
| Q3 2021 | $301,000 | +7.9% | 9,401 | +3.6% | 0.00% | 0.0% |
| Q2 2021 | $279,000 | -14.7% | 9,071 | -6.6% | 0.00% | -33.3% |
| Q1 2021 | $327,000 | -6.3% | 9,715 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $349,000 | -5.4% | 9,667 | -3.6% | 0.00% | -25.0% |
| Q3 2020 | $369,000 | +10.8% | 10,028 | +35.8% | 0.00% | -20.0% |
| Q2 2020 | $333,000 | -14.4% | 7,384 | -9.9% | 0.01% | -28.6% |
| Q1 2020 | $389,000 | – | 8,192 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |